Slide 1: 2016 Preliminary FY results
2016 Preliminary FY results MILAN – 9 FEBRUARY 2017
Slide 2: Full year 2016 highlights
Full year 2016 highlights • Revenue € 1,153.9 million, up 10.1% • EBITDA € 371.2 million or 32.2% of sales, up 17.1% • Operating income (EBIT) € 327.4 million or 28.4% of sales, up 17.6% • Net income € 237.4 million or 20.6% of sales, up 19.4% • Net debt € 198.8 million, an increase of € 110.0 milli
Slide 3: Main product sales
Main product sales Corporate products including drugs for rare diseases account for 61.2% of revenue (million Euro) 2016 2015 Change % Zanidip® (lercanidipine) 114.0 115.7 (1.5) Zanipress® (lercanidipine+enalapril) 69.1 65.7 5.2 Urorec® (silodosin) 85.2 68.3 24.8 Livazo® (pitavastatin) 35.1 28.4 23.
Slide 4: A diversified product portfolio
A diversified product portfolio Other corporate products 13.4% Drugs for rare diseases 16.2% Livazo® 3.0% Urorec® 7.4% Zanipress® 6.0% OTC 16.1% Zanidip® 9.9% Subsidiaries’ local product portfolios 23.6% Pharmaceutical chemicals 3.5% Ortoton® (methocarbamol) - Germany 3% Other revenue 0.9% Methadone
Slide 5: Composition of revenue by geography
Composition of revenue by geography Sustained growth (million Euro) 2016 2015 Change % Italy 229.9 204.8 12.2 France 115.1 110.6 4.0 U.S.A. 101.1 82.1 23.2 Germany 101.1 94.8 6.7 Turkey 86.3 74.1 16.5 Russia, other CIS countries and Ukraine 79.5 72.4 9.9 Spain 76.4 72.0 6.2 North Africa 42.3 43.7 (3
Slide 6: Geographical breakdown of pharmaceutical revenue
Geographical breakdown of pharmaceutical revenue Other international sales 15.2% (sales to licensees and exports) Italy 20.6% Other CEE 2.9% Other W. Europe 3.6% Portugal 3.6% France 10.3% North Africa 3.8% Spain 6.9% U.S.A. 9.1% Russia, other CIS and Ukraine 7.1% Turkey 7.8% Germany 9.1% Data: Full
Slide 7: Full year 2016 results: Further margin growth
Full year 2016 results Further margin growth (million Euro) 2016 2015 Change % Revenue 1,153.9 1,047.7 10.1 Gross Profit 793.0 712.5 11.3 as % of revenue 68.7 68.0 SG&A Expenses 369.2 352.2 4.8 as % of revenue 32.0 33.6 R&D Expenses 83.7 76.7 9,1 as % of revenue 7.3 7.3 Other Income (Expense), net (
Slide 8: Full year 2016 results: Operating segments
Full year 2016 results Operating segments Revenue EBIT Treatments for rare diseases 16.2% Treatments for rare diseases 25.5% Primary & specialty care Primary & specialty care 83.8% 74.5% EBIT margin on sales: Treatments for rare diseases, 44.6% Primary & Specialty care, 25.2% (or 26.0% excluding non
Slide 9: Net financial position
Net financial position (million Euro) 31 Dec 2016 31 Dec 2015 Change Cash and short-term financial 138.5 225.5 (87.0) investments Bank overdrafts and short-term loans (15.7) (9.8) (5.8) Loans – due within one year (40.4) (34.5) (5.9) Loans – due after one year (281.1) (269.9) (11.2) NET FINANCIAL PO
Slide 10: Company declarations, disclaimers and profile
Company declarations, disclaimers and profile DECLARATION BY THE MANAGER RESPONSIBLE FOR PREPARING THE COMPANY’S FINANCIAL REPORTS The manager responsible for preparing the company’s financial reports Fritz Squindo declares, pursuant to paragraph 2 of Article 154-bis of the Consolidated Law on Finan